RAPID Reserve Act
- Bill Number
- H.R. 3955
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-12: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-01-14T05:02:30Z
AI-Generated Summary
Purpose of the Legislation
The Rolling Active Pharmaceutical Ingredient and Drug Reserve Act (RAPID Reserve Act) aims to strengthen the U.S. drug supply chain by creating reserves of critical drugs and their active pharmaceutical ingredients (APIs, which are the key chemical components that make drugs effective). It focuses on drugs with weak or risky supply chains to prevent shortages during public health emergencies, natural disasters, or threats like chemical, biological, radiological, or nuclear events.
Key Provisions
- Establishment of Reserves Program: The Secretary of Health and Human Services (HHS) must award contracts or cooperative agreements to qualified organizations (eligible entities) for drugs and APIs identified as critical and having vulnerable supply chains (e.g., due to limited manufacturers, geographic concentration of production, or quality issues). HHS must publish a public list of these drugs and APIs.
- Reserve Maintenance Requirements: Eligible entities must:
- Keep a 6-month supply (or another amount set by HHS) of APIs and finished drugs in approved U.S. or certain foreign facilities (in countries belonging to the Organisation for Economic Co-operation and Development, or OECD, a group of developed nations).
- Regularly refresh these reserves with newly made supplies.
- Ramp up production of the drug or API when directed by HHS.
- Share parts of API reserves with other manufacturers if needed to address shortages, or allow HHS to redirect them during emergencies.
- Guidance and Eligibility: Within 180 days of the law's enactment, HHS, working with the Food and Drug Administration (FDA), must issue guidance on:
- How to identify vulnerable supply chains and how contracts can reduce risks.
- What makes an entity eligible, emphasizing quality manufacturing, domestic production capacity, and ability to surge output.
- Rules for award recipients, including excess capacity, backups, and quality standards.
- Preferences and Award Criteria: HHS must prioritize entities using U.S. facilities or sourcing materials from the U.S. or OECD countries. Awards should promote domestic manufacturing, reduce costs, ensure quality, and build surge capacity while encouraging market competition.
- Contract Terms: Contracts can include rules for buying, storing, testing, and delivering drugs, and may fund building or upgrading non-government facilities to improve preparedness.
- Definitions:
- Eligible Drug: A FDA-approved or licensed drug vital for emergencies or threats, where shortages could harm the healthcare system or vulnerable groups, and with a fragile supply chain.
- Eligible Entity: Drug manufacturers, API producers (in partnership with drug makers), or distributors/wholesalers with strong safety records and approved facilities.
- Reporting and Funding: HHS must report to Congress every two years on selected drugs and program effectiveness (without revealing security-sensitive details). The law authorizes $500 million for fiscal year 2026 to implement it.
Significant Changes to Existing Law
This bill introduces a new federal program under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to mandate and fund strategic reserves for critical drugs and APIs, which is not currently required. It builds on existing FD&C Act definitions (e.g., for drug shortages and facility registration) but adds preferences for domestic or OECD-based production, reserve-sharing mechanisms, and emergency allocation powers for HHS. It also allows federal funding for private facility improvements, overriding some limits in federal procurement law (41 U.S.C. § 6303).
Potential Impacts
- On Government Agencies: HHS and FDA gain new responsibilities to identify risks, award contracts, and manage reserves, requiring coordination with agencies like the Centers for Disease Control and Prevention (CDC) and the Assistant Secretary for Preparedness and Response. This could strain resources but enhance emergency response capabilities.
- On Citizens: Improves access to essential medications during crises, potentially reducing health risks from shortages for patients, especially at-risk groups (e.g., those needing treatments for infections or chronic conditions).
- On International Relations: Shifts reliance toward U.S. or OECD sources, which may reduce dependence on non-OECD suppliers (e.g., in Asia) and encourage allied nations to align on supply chain standards, but could strain trade ties with other global partners.
Main Stakeholders Affected
- Drug and API Manufacturers: Must maintain reserves and meet quality standards; benefit from funding and preferences for domestic operations.
- Distributors and Wholesalers: Can participate in partnerships but face new sharing obligations.
- Government Entities: HHS, FDA, and CDC lead implementation; Congress oversees via reports.
- Healthcare Providers and Patients: Gain more reliable drug supplies, particularly for critical needs.
- U.S. Economy: Boosts domestic manufacturing jobs and infrastructure.
Notable Legal, Constitutional, or Political Implications
- Legal: Expands HHS authority over private supply chains without new regulatory burdens on all drugs, focusing only on "eligible" ones; aligns with FD&C Act but introduces enforceable reserve contracts, potentially leading to disputes over vulnerability assessments or preferences.
- Constitutional: Relies on Congress's spending power to fund private entities, which is standard but could face challenges if seen as favoring certain manufacturers over free market principles.
- Political: Promotes national security through self-reliance in pharmaceuticals, a bipartisan priority amid past shortages (e.g., during COVID-19); the $500 million authorization signals commitment but may spark debates on costs versus benefits in future budgets.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Rep. Van Drew, Jefferson [R-NJ-2]
Recent Actions
- 2025-06-12: Referred to the House Committee on Energy and Commerce.
- 2025-06-12: Introduced in House
- 2025-06-12: Introduced in House
Bill Versions
- Rolling Active Pharmaceutical Ingredient and Drug Reserve Act — issued 2025-06-12 — PDF (11 pages)